The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...

BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it ...

About two thirds of those at-risk for influenza are yet to be vaccinated this winter, according to Public Health Scotland.